Every year, International Clinical Trials Day highlights the role of clinical research in advancing medicine and improving patient care.
Clinical trials remain essential for understanding whether new therapeutic approaches are safe, effective and meaningful for patients. But in rare diseases, generating robust clinical evidence is often particularly complex.
Traditional clinical research models were largely developed for common conditions affecting large patient populations. Rare diseases present a very different reality. Small patient cohorts, heterogeneous disease progression, limited datasets and complex recruitment pathways create important methodological challenges across the entire research process.
For researchers working in rare diseases, this raises an important question: how can research approaches evolve to better reflect the realities of small and highly diverse patient populations?
The challenge of research in rare diseases
Rare diseases affect relatively small numbers of patients, often dispersed across different countries and healthcare systems. In many cases, collecting sufficiently robust and comparable datasets can become difficult.
Patients may present different disease stages, progression rates or clinical manifestations, making direct comparisons more complex. Recruitment for clinical studies may also require extensive coordination between clinical centres, researchers, healthcare professionals and patient organisations.
These challenges influence not only clinical trials themselves, but also the earlier stages of translational research that support therapeutic development.
Understanding disease mechanisms, identifying biomarkers, validating experimental models and generating reproducible data all become especially important in research environments where available data may already be limited.
Why flexibility matters in rare disease research
As a result, researchers are increasingly exploring more flexible and data-driven approaches adapted to the specific constraints of rare diseases.
This includes:
- The use of patient-derived cellular models
- Integration of imaging, molecular and computational data
- AI-supported analysis of biological pathways
- Development of structured and reproducible datasets
- Adaptive research methodologies capable of working with smaller populations
The objective is not to reduce scientific rigour, but to generate robust and meaningful evidence under conditions where every dataset and every biological sample become particularly valuable.
In rare diseases, the quality, reproducibility and interpretability of the data generated are often closely linked to the overall efficiency of the research process itself.
Building research pipelines adapted to small patient populations
One of the major challenges in rare disease research is ensuring that experimental observations remain reproducible and comparable across different studies and research models.
This is why many projects increasingly focus on building structured research pipelines capable of integrating multiple data types and methodologies within a common framework.
Patient-derived models, advanced imaging approaches, omics analyses and computational methods can all contribute to a more comprehensive understanding of disease-related mechanisms.
At the same time, these approaches require careful validation and standardisation to ensure that results remain interpretable, reproducible and reusable across research environments.
Balancing methodological innovation with scientific robustness is becoming increasingly important in rare disease research.
How this connects to DREAMS
Within the DREAMS project, these questions are part of a broader effort to support research in rare neuromuscular disorders through structured biological and computational approaches.
DREAMS combines patient-derived cellular models, molecular analysis, imaging data and artificial intelligence methods to study shared disease mechanisms and support drug repurposing research in muscular disorders.
By integrating biological and computational methodologies, the project contributes to ongoing efforts to improve how rare disease research can be conducted in contexts where datasets are limited and experimental reproducibility is essential.
While DREAMS is not a clinical trial project, many of the broader challenges highlighted on International Clinical Trials Day, including methodological robustness, evidence generation and the complexity of working with small patient populations, are highly relevant to the research landscape in which the project operates.
Clinical research as a collective effort
Clinical research depends on the contribution of many different actors.
Patients and families participate in studies and share valuable experiences and data. Clinicians coordinate care and research activities. Researchers develop experimental models, methodologies and analytical approaches. Regulatory and healthcare stakeholders help establish scientific and ethical standards.
In rare diseases, collaboration between these communities becomes particularly important.
International Clinical Trials Day is therefore not only an opportunity to recognise the importance of clinical studies themselves, but also the broader research ecosystem required to support future therapeutic innovation.
Advancing rare disease research depends not only on scientific discovery, but also on developing research approaches capable of working effectively within the realities of rare disease populations
